“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI […]